Companies › Chengdu Origen Biotechnology
2 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KH631 AAV vector-based gene therapy expressing anti-VEGF protein | VEGFA | Phase 1 | Age-Related Macular Degeneration | Dec 2026 |
| KH658 AAV vector delivering anti-VEGF protein | VEGFA | Phase 1 | Age-related Macular Degeneration; Age-Related Macular Degeneration | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06458595 | KH658 | Phase 1 | Age-related Macular Degeneration | Ophthalmology | Dec 2026 |
| NCT05672121 | KH631 | Phase 1 | Age-Related Macular Degeneration | Ophthalmology | Dec 2026 |
| NCT06825858 | KH658 | Phase 1 | Age-Related Macular Degeneration | Ophthalmology | Jan 2027 |
| NCT05657301 | KH631 | Phase 1 | Age-Related Macular Degeneration | Ophthalmology | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.